Skip to main content

Advertisement

General principles and escalation options of immunotherapy in autoantibody-associated disorders of the CNS

Article metrics

Abstract

Autoimmune diseases associated with antineuronal and antiglial autoantibodies (Abs) is one of the most rapidly expanding research fields in clinical neuroimmunology, with more than 30 autoantibodies described so far. Being associated with a wide range of clinical presentations these syndromes can be diagnostically challenging. Surface or intracellular antigen localizations are crucial for the treatment response and outcome. In the latter Abs are mostly of paraneoplastic cause and tumor management should be performed as soon as possible in order to stop peripheral antigen stimulation. Immunotherapy should be started early in both groups, before irreversible neuronal loss occurs. Despite serious prognosis, aggressive therapeutic approaches can be effective in many cases. In this article we review main pathogenic mechanisms leading to Abs-related syndromes and describe standard as well as emerging strategies of immunotherapy, including tocilizumab and bortezomib. Several special therapeutic approaches will be illustrated by clinical cases recently treated in our department.

Introduction

Autoimmune diseases associated with antineuronal and antiglial autoantibodies (Abs) is one of the most rapidly expanding research fields in clinical neuroimmunology. Autoantibodies targeting more than 30 specific antigens in the central nervous systems (CNS) have been identified so far and several new candidate antigens are reported every year [1]. Intracellular or surface target protein localisation and in the last case its function often determine clinical presentation as well as key immunological mechanisms and accordingly preferable therapeutic approaches. Rarity and clinical diversity of the Abs-associated syndromes, lack of specific clinical features and partly overlapping symptoms are challenging for diagnostics. Studies on management are generally limited and large double-blind clinical trials have been conducted in neuromyelitis optica spectrum disorder (NMOSD) only [2]. Experience gathered from NMOSD management is useful, however, cannot be automatically transferred to other diseases associated with antineuronal Abs due to pathogenic differences. Treatment recommendations are mostly based on retrospective case series and expert opinions. Although several generally accepted therapy principles have been elaborated in the last decades, an individual strategy is often required, especially in rare syndromes and/or therapy refractory cases. Here, we discuss principles of management of Abs-associated CNS-diseases and describe several challenging cases, recently treated in our department.

Abs directed towards intracellular antigens

The Abs targeting intracellular proteins are mostly (with an exception of Abs against GAD-65 (glutamate decarboxylase)) of paraneoplastic origin and associated with tumors, expressing neuronal antigens or directed against ubiquitous nuclear antigens released due to continuous cell death in progressive tumors. It is believed, that the anti-tumor immune response partly supresses tumor growth, thereby resulting in a breakthrough of the immunological tolerance with development of an autoimmune disease. This hypothesis explains well an early manifestation of neurological syndromes, in 2/3 of cases prior to cancer diagnosis [3]. The increasing number of reports on paraneoplastic syndromes (PNS) under tumor therapy with checkpoint inhibitors also supports this theory [4]. Due to an intracellular Ag-localization onconeuronal Abs are probably not involved into pathogenesis, however serve as an important diagnostic epiphenomenon. In contrast, a T-lymphocyte mediated immune response results in a rapid irreversible neuronal loss within several weeks or months leading to permanent deficits [5]. Accordingly, the stroke principle “time is brain” is also relevant in PNS. An early tumor treatment is the most important management step. Prompt removal or depletion of tumor cells, as a source of peripheral antigen stimulation, decreases activity of the autoimmune response and can alone be sufficient for stabilization or even improvement of the PNS [6,7,8].

Despite an overall clinical heterogeneity, several red flags can be helpful for the early diagnostics of PNS:

  • mostly subacute manifestation with continuous progression over weeks or months;

  • disease manifestation at age > 45 years (with a few exceptions, e.g. opsoclonus-myoclonus syndrome in children, teratoma-associated anti-NMDAR (N-methyl-D-aspartate receptor) encephalitis in young females or Ma2-Abs in men < 50 years);

  • typical clinical manifestations (without a plausible alternative explanation): subacute cerebellar degeneration, brainstem or limbic encephalitis, opsoclonus-myoclonus syndrome, stiff-person syndrome, sensory neuronopathy, neuromyotonia or Lambert-Eaton syndrome;

  • sometimes multilocular manifestation (e.g. in both central and peripheral nervous system).

Cerebrospinal fluid analysis may reveal non-specific inflammatory changes and MRI is mostly normal or may rarely demonstrate characteristic symmetric inflammatory lesions (e.g. in the cerebellum in subacute cerebellar atrophy) in early stages and atrophy in late stages.

It is generally accepted that the first line immunotherapy should be initiated early, preferably within a few weeks after disease manifestation, even before definite identification of the underlying tumor [9,10,11]. In most cases adequate immunosuppressive therapy does not affect tumor diagnostics (exception: steroid therapy in suspected lymphoma) as well as tumor outcome [12].

Tumor detection

Since the autoimmune response suppresses tumor growth, the tumors are often initially small and asymptomatic [3, 13]. PNS are mostly associated with lung cancer (small cell > > non-small cell lung cancer), ovarian and breast cancer, Hodgkin and non-Hodgkin lymphoma or thymoma [3, 14]. Presence of several antineuronal Abs in one patient is not rare and helps to narrow further diagnostic workup [15, 16]. In special situations a testicular cancer (in men younger than 50 years with Ma2-Abs) and neuroblastoma (in children with opsoclonus-myoclonus syndrome or rarely Hu-Abs) should be considered [17, 18]. Depending on suspected malignancy, a targeted diagnostic approach should be performed [13]. If standard diagnostic work-up remains negative, a whole-body FDG-PET/CT can be helpful [19]. If FDG-PET/CT is negative, tumors with low proliferation rates (e.g. differentiated teratomas, neuroendocrine tumors) or non–metastatic skin cancers should be considered. Rarely even thorough first tumor screening may remain negative. Further diagnostic assessment is recommended within 3 months and then every 6 months for a period of 4 years [13].

Abs directed toward surface antigens

In contrast, Abs targeting surface antigens are only facultative of paraneoplastic origin and often occur as a primary autoimmune disorder, especially in younger patients. Loss of function of surface target proteins, including synaptic receptors, ion channels or associated membrane proteins, explain direct pathogenic significance of autoantibodies. Interestingly, the clinical presentation is often similar to genetic disorders with mutations in the same target protein (e.g. focal seizures in LGI1-Abs (leucine rich glioma inactivated 1) and familial temporal lobe epilepsy with mutation in the LGI1 gene [20, 21]. Several immunologic mechanisms have been described in this subgroup of Abs-associated diseases so far [22]:

  • receptor cross-linking and internalization, resulting in a decreased receptor density in the synapse;

  • direct agonistic or antagonistic action on the receptor itself;

  • activation of the complement cascade or antibody-dependent cell-mediated cytotoxicity (with irreversible deficits).

The respective IgG-subclass may contribute to the pathogenesis and should be considered by choosing the best suited therapy. Although being usually of IgG1 subclass, several Abs (e.g. LGI1-, CASPR2- (contactin associated protein 2), IgLON5- etc.) predominantly belong to the IgG4 subclass. Being able to exchange half-molecule (so called “Fab-arm exchange”) IgG4 are bispecific and functionally monovalent [23]. Moreover, they have low affinity for the Fcγ receptor. Accordingly, autoantibodies of IgG4 subclass cannot induce cross-linking, complement activation or cell-mediated cytotoxicity. Abs-related interference of the ligand-receptor interaction has been supposed as one of possible pathogenic mechanisms in IgG4-related neurologic disorders [24]. Yet a combination of autoantibodies from several subclasses can be found in most cases, making interpretation of the precise pathogenic mechanisms difficult.

Due to a direct pathogenic role of autoantibodies, Abs-depleting immunotherapies, including apheresis in the acute stage and B-cell targeting long-term therapies are effective in most cases. If treated appropriately, an outcome in case of Abs targeting surface proteins is considerably better, comparing to classical PNS, associated with immune responses against intracellular antigens. An early start of the first line therapy is associated with a better long-term outcome in those syndromes [25, 26].

General principles of immunotherapy

Main therapy regimens are summarized in the Table 1. In both paraneoplastic and primary autoimmune forms first line treatment at the acute stage usually includes either corticosteroid pulse therapy (e.g. 5 × 1000 mg methylprednisolone IV, in some cases followed by oral tapering) or intravenous immunoglobulin G (IVIG, e.g. 0.4 g/kg bodyweight for 5 days). If no sufficient improvement can be achieved, an early escalation to immunoadsorption or plasma exchange should be undertaken. IVIG treatment and apheresis therapies are especially effective in case of Abs directed against surface antigens compared to intracellular antigens [9, 27,28,29]. If no improvement occurs, an early (up to 2 weeks after the primary treatment) escalation to cyclophosphamide (as a short-term high-dose treatment with 750–1000 mg/m2 IV) or rituximab (e.g. 500 mg – 1000 mg IV) can be performed [9, 30, 31]. Treatment of paraneoplastic cases is often challenging and tumor therapy is most important for stabilization of the neurological deficits [6,7,8].

Table 1 Standard therapeutic approach and escalation therapies

Depending on the risk of further relapses or progression a limited (e.g. for 1–2 years by teratoma-associated NMDAR-Abs encephalitis) or a life-long immunotherapy can be required (Table 1). Long-term treatment usually includes oral immunosuppressants (e.g. azathioprine 2–3 mg/kg/d, mycophenolate mofetil 250–1000 mg b.i.d. as a monotherapy or combined with oral steroids) or rituximab (e.g. 500 mg every 6 months). In some syndromes regular IVIG courses (usually 1 g/kg bodyweight every 4 to 8 weeks) can be effective (e.g. stiff-person syndrome, myelin oligodendrocyte glycoprotein (MOG) - Abs associated disease, IgLON5-syndrome).

Regular monitoring of both clinical (e.g. cognitive deficits, frequency and severity of seizures, spasticity, degree of ataxia etc.) and paraclinical (e.g. MRI-changes, intraindividual changes of Abs-titers, especially in CSF, or epileptiform activity in Video-EEG monitoring) disease activity is critically important in order to evaluate therapy responsiveness. We recommend an early first follow-up examination within 1–3 months after initiation of the immunotherapy. Further follow-up intervals can be extended and should be performed every 6–12 months, depending on the clinical entity and individual course of the disease.

Outcome

Outcome in classical paraneoplastic syndromes is usually poor with a relative exception of Ma2-Ab-associated encephalomyelitis, in which approx. 30% of patients experience improvement after adequate tumor treatment and immunotherapy [32]. In contrast, patients with Abs targeting surface antigens have a much better prognosis, except for those with additional onconeural Abs [33, 34]. Especially in case of Abs-mediated cross-linking and internalization of the target–receptor-antibody complex together with Abs no or only minor neuronal loss occurs [35, 36]. This mechanism explains good or even complete recovery in about 75% of patients with NMDAR-encephalitis [37]. Still therapy refractory cases occur also in this group [38, 39]. It is supposed that main reasons might be compartmentalization of the immune response in the CNS (e.g. in NMDAR-encephalitis) and non-responsiveness of long-lived CD20-negative Abs-producing plasma cells to classical immunosuppressive agents and rituximab.

Escalation therapies targeting plasma cells

In therapy refractory cases with a rapid ongoing clinical deterioration, prompt escalation to therapies directly targeting Abs-producing plasma cells can be critically important. Two of the most promising and already tested options include the anti-IL-6 receptor monoclonal antibody tocilizumab and the proteasome inhibitor bortezomib.

In NMOSD, three new substances are currently under investigation: the anti-IL-6 receptor antibody satralizumab (2nd generation substance following tocilizumab), the anti-CD19 monoclonal antibody inebilizumab and the anti-C5 complement factor directed antibody eculizumab. Belimumab, a monoclonal antibody targeting B-cell activating factor (BAFF), could also be potentially effective, however there is no real-life clinical experience with this substance in neurological diseases published so far.

Tocilizumab

Tocilizumab is a humanized monoclonal antibody, targeting both soluble and membrane bound IL-6-receptor, approved in rheumatoid arthritis and juvenile idiopathic polyarthritis and giant cells arteritis. The IL-6 pathway plays an important role in various autoimmune diseases, being involved into differentiation of Abs-producing B-cells as well as IL-17 producing T-helper cells and IL-21-producing CD8+ T-cells [40, 41]. In NMOSD a specific CD19intCD27highCD38highCD180 plasmablast subpopulation has been reported to produce AQP4 (aquaporin4)-Abs in an IL-6 dependent manner [42]. In 2013 we reported for the first time effective treatment of rituximab-refractory NMOSD patients with tocilizumab (8 mg/kg every 4 weeks) [43]. Both relapse activity and AQP4-Abs titer in serum decreased without serious side effects, with the longest therapy duration of 8 years in one patient so far. In some of these patients AQP4-Abs are not detectable any more (unpublished data).

In a recent phase 3 clinical trial satralizumab, a new long-circulating humanized monoclonal antibody targeting the IL-6 receptor, demonstrated impressive efficacy, especially in seropositive NMOSD [2]. Tocilizumab was also effective in refractory cases of contactin-associated protein-like 2 and NMDAR-encephalitis [39, 44]. Recently we started tocilizumab in two patients with an aggressive and therapy resistant MOG-Abs positive NMOSD. Previous therapies including azathioprine and rituximab in combination with oral prednisolone (20–30 mg/d) were not effective and patients developed multiple relapses approximately every 8 weeks. No further relapses occurred during the last months on tocilizumab therapy, however further and longer observations are needed (unpublished data).

Taken altogether, we suppose that tocilizumab is a promising second-line therapy in syndromes with Abs targeting surface proteins. Tocilizumab should be given in a dose of 8 mg/kg every 4 weeks. As previously demonstrated, prolonged intervals are associated with further relapse activity, at least by AQP4-Abs positive NMOSD [45]. Based on a large rheumatologic experience this therapy option is relatively safe in our region [46]. However, neutropenia, thrombocytopenia, elevated liver enzymes and hypercholesterinemia may rarely occur. Risk of infections is increased and should be thoroughly clinically monitored, as impaired IL-6 signaling results in usually normal C-reactive protein and normal body temperature even despite systemic infection.

Bortezomib

Bortezomib is a selective reversible inhibitor of the enzymatic activity of the 20S proteasome subunit, approved for the treatment of multiple myeloma [47, 48]. Due to a high metabolic activity professional Abs-producing plasma cells are especially susceptible to proteasome blockade. Mechanistically, bortezomib causes an aberrant degradation and accumulation of defective ribosomal products in the endoplasmic reticulum. At the same time bortezomib decreases the degradation of the antiapoptotic nuclear factor kB (NF-kB) inhibitor, enhancing apoptosis in both myeloma and plasma cells. Furthermore, decreased activity of the NF-kB pathway results in a profound suppression of proinflammatory cytokines such as tumor necrosis factor alpha (TNF-α), IL-1β, IL-6, reduction of T-cell activation and induction of apoptosis in already activated and proliferating T-cells [49, 50]. Reduced protein degradation limits presentation of autoantigens to the immune system. Moreover, bortezomib impairs maturation of professional Ag-presenting dendritic cells (DC) and subsequently DC-mediated T-cell stimulation, especially demonstrated for alloreactive T-cells [51, 52].

Bortezomib has been successfully used in several rheumatologic diseases, including rheumatoid arthritis and refractory systemic lupus erythematosus [53, 54]. In the latter bortezomib induced a transient decrease of anti-ds-DNA-Abs. However, Abs recurred after bortezomib withdrawal, due to a rapid repopulation of plasma cells [55]. Accordingly, a combination of bortezomib with rituximab seems to be essential for a sustained response in chronic autoimmune diseases. Interestingly, in vitro data demonstrate that bortezomib-induced impaired intracellular degradation of CD20 results in its upregulation on the surface of lymphoblastoid B-cells [56]. Thus, it may increase the therapeutic effect of rituximab, supporting the rationale for a combination therapy with both medications. The small size and good permeability through the blood-brain barrier is an important advantage of bortezomib in neurological conditions, compared to large Abs-molecules, especially in case of intrathecal compartmentalization of the autoimmune response.

Experience in neurological diseases is limited. In 2016 we reported the first two patients with severe NMDAR-encephalitis responsive to bortezomib [57]. Our first patient, previously mechanically ventilated over 7 months and refractory to IVIG, corticosteroids, plasma exchange, rituximab and cyclophopsphamide, improved almost completely (except for mild cognitive deficits) under bortezomib. A second patient improved initially well under plasma exchange and rituximab, however relapsed 20 months later despite complete B-cell depletion. She was refractory to all first line therapies, including plasma exchange and achieved significant improvement after initiation of bortezomib mono-therapy only. Several further case reports and case series confirmed bortezomib as a promising escalation therapy in NMDAR-encephalitis recently [58,59,60].

Similar efficacy in other syndromes is likely associated with immune response against membrane antigens. Recently we reported the first positive experience in myasthenia gravis. A patient with anti-muscle-specific tyrosine kinase (MuSK)-Abs, previously non-responsive to high-dose IVIG, apheresis therapy, steroids and rituximab showed rapid and significant clinical improvement upon bortezomib therapy [61]. A phase IIa clinical trial investigating efficacy of bortezomib in myasthenia gravis, lupus erythematosus and rheumatoid arthritis is ongoing [62].

Here, we describe a 20-year old man who developed anti-glycine receptor mediated epilepsy and was successfully treated with a combination therapy of rituximab and bortezomib (Table 2 , Fig. 1).

Table 2 Case Box 1
Fig. 1
figure1

Frequency of absence episodes and titers of anti-glycine receptor-Abs in relation to the course of therapy. Please note that the timeline on the x-axis is nonlinear

Suppression of humoral autoimmunity explains many, but not all effects of proteasome inhibitors. Recently we observed significant clinical improvement under bortezomib in a patient with severe subacute cerebellar ataxia associated with Abs targeting neurochondrin and Delta notch-like epidermal growth factor-related receptor (DNER) (Table 3 , Fig. 2). DNER is a transmembrane protein, so that a direct pathogenic role of Abs cannot be excluded [63]. Still, previous studies could not confirm efficacy of the Abs-depleting therapy in this obligate paraneoplastic syndrome. Usually, it has a progressive course with irreversible deficits and poor functional outcome despite plasma exchange therapy [64]. Neurochondrin is located intracellularly and an antigen-specific T-cell response, but not autoantibodies, seems to be pathogenically relevant [65]. Interestingly, bortezomib administration also resulted in stabilization or even improvement in 10 patients with chronic inflammatory demyelinating polyneuropathy, classically histopathologically characterized by macrophage and T-lymphocyte infiltration [66]. None of these patients had specific nodal or paranodal autoantibodies. If bortezomib, due to its pleiotropic effects, could be effective in other diseases associated with a T-cell mediated immunity and intracellular antigen localization, remains highly speculative and should be investigated in the future. However, if effective, it would be an important treatment option in otherwise refractory classical paraneoplastic syndromes.

Table 3 Case box 2
Fig. 2
figure2

Walking distance and anti-neurochondrin-Abs titers in relation to the course of therapy. Please note that the timeline on the x-axis is nonlinear

Sensory axonal polyneuropathy is one of the most important limiting side effects of bortezomib, reaching a prevalence of 30–60% by high-dose treatment in multiple myeloma [67, 68]. In autoimmune conditions usually lower doses are sufficient. Further serious adverse events include pancytopenia, congestive heart failure, pulmonary edema, renal failure, gastrointestinal bleedings or infectious complications [69].

Future promising options

Besides the above mentioned satralizumab, two further medications, targeting humoral autoimmunity and being currently investigated in NMOSD, could be promising in other Abs-mediated CNS diseases. Eculizumab is a humanized monoclonal IgG4 antibody, inhibiting cleavage of C5 complement factor into proinflammatory cell-activating C5a and lytic terminal complex component C5b. It is approved for the treatment of paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome and refractory myasthenia gravis [70, 71]. Recently, a successful phase 3 study of eculizumab in AQP4-Abs positive NMOSD has been reported [72]. Eculizumab could be an interesting escalation therapy in other diseases, associated with complement activating IgG1-Abs. Despite its poor blood-brain-barrier permeability (serum: CSF ratio 1:5000), eculizumab significantly decreases C5 concentration in the CSF [73]. Moreover, due to a rapid decrease of the complement activity it could be effective and especially attractive during the acute stage of diseases, associated with complement activating IgG1-Abs. Main safety concerns include risk of infectious, particularly with encapsulated bacteria. Eculizumab therapy is associated with a 1000-fold to 2000-fold increased incidence of meningococcal disease, despite tetravalent meningococcal vaccination [74].

Inebilizumab is an afucosylated monoclonal humanized IgG1, targeting CD19 of B-cells. The absence of fucose results in increased antibody dependent cellular cytotoxicity [75]. Potential advantages of anti-CD19 compared to anti-CD20 therapy are the depletion of later stage CD20-negative Abs-producing B-cells, including plasmablasts and some plasma cells. Preclinical data support greater effect of anti-CD19 therapy on B-cell driven autoimmunity [76]. Also, the aforementioned subpopulation of NMOSD-specific plasmablasts express CD19, but not CD20 [42]. The possibility to translate this extended spectrum of targeted B-cells into additional clinical benefits without a higher risk of serious infections must be addressed in further clinical trials. Inebilizumab demonstrated an acceptable safety profile in a phase I study in RRMS and systemic sclerosis and detailed results of the positive phase II/III study in NMOSD are not published yet [77, 78].

Conclusion

In summary, both localization and function of the target antigen as well as predominant IgG-subtype and/or involvement of T-cell autoimmunity determine therapy responsiveness and outcome in Abs-mediated neurological syndromes. Treatment should be started as early as possible and an increased diagnostic vigilance is required. In refractory cases prompt therapy escalation should be considered. Individual treatment decisions, including immunotherapies established in rheumatologic or oncological diseases, can result in breakthrough improvement. In case of intracellular antigen localization outcome remains poor, therefore new treatment strategies are urgently needed.

Availability of data and materials

Not applicable.

Abbreviations

Abs:

autoantibodies

AQP4:

aquaporin4

CASPR2:

contactin associated protein 2

CNS:

central nervous systems

CT:

computer tomography

DC:

dendritic cells

DNER:

delta notch-like epidermal growth factor-related receptor

FDG-PET:

fluorodeoxyglucose positron emission tomography

GAD:

glutamate decarboxylase

IA:

immunoadsorption

IL:

interleukin

IV:

intravenous

IVIG:

intravenous immunoglobulin G

LGI1:

leucine rich glioma inactivated 1

MOG:

myelin oligodendrozyten glycoprotein

MuSK:

muscle-specific tyrosine kinase

NF-kB:

nuclear factor kB

NF-kB:

nuclear factor kB

NMDAR:

N-methyl-D-aspartate receptor

NMOSD:

neuromyelitis optica spectrum disorder

PE:

plasma exchange

PNS:

paraneoplastic syndromes

TNF-α:

tumor necrosis factor alpha

References

  1. 1.

    Scharf, M., Miske, R., Kade, S., et al. (2018). A Spectrum of neural autoantigens, newly identified by Histo-immunoprecipitation, mass spectrometry, and recombinant cell-based indirect immunofluorescence. Frontiers in Immunology, 9, 1447. https://doi.org/10.3389/fimmu.2018.01447.

  2. 2.

    A. Traboulsee , B. Greenberg , J.L. Bennett , L. Szczechowski , E. Fox , S. Shkrobot , T. Yamamura , Y. Terada , Y. Kawata , A. Melia , A. Gianella-Borradori , B.G. Weinshenker. A double-blind placebo-controlled study of satralizumab (SA237), a recycling anti-IL-6 receptor monoclonal antibody, as monotherapy for patients with neuromyelitis optica spectrum disorder (NMOSD). ECTRIMS Online Library. Oct 12, 2018; 229118.

  3. 3.

    Giometto, B., Grisold, W., Vitaliani, R., et al. (2010). Paraneoplastic neurologic syndrome in the PNS Euronetwork database: A European study from 20 centers. Archives of Neurology, 67(3), 330–335. https://doi.org/10.1001/archneurol.2009.341.

  4. 4.

    Dalakas, M. C. (2018). Neurological complications of immune checkpoint inhibitors: What happens when you “take the brakes off” the immune system. Therapeutic Advances in Neurological Disorders, 11, 1756286418799864. https://doi.org/10.1177/1756286418799864.

  5. 5.

    Bauer, J., & Bien, C. G. (2016). Neuropathology of autoimmune encephalitides. Handbook of Clinical Neurology, 133, 107–120. https://doi.org/10.1016/B978-0-444-63432-0.00007-4.

  6. 6.

    Graus, F., Keime-Guibert, F., Reñe, R., et al. (2001). Anti-Hu-associated paraneoplastic encephalomyelitis: Analysis of 200 patients. Brain: A Journal of Neurology, 124(Pt 6), 1138–1148.

  7. 7.

    Shams’ili, S., Grefkens, J., de Leeuw, B., et al. (2003). Paraneoplastic cerebellar degeneration associated with antineuronal antibodies: Analysis of 50 patients. Brain: A Journal of Neurology, 126(Pt 6), 1409–1418.

  8. 8.

    Candler, P. M., Hart, P. E., Barnett, M., Weil, R., & Rees, J. H. (2004). A follow up study of patients with paraneoplastic neurological disease in the United Kingdom. Journal of Neurology, Neurosurgery, and Psychiatry, 75(10), 1411–1415. https://doi.org/10.1136/jnnp.2003.025171.

  9. 9.

    Vernino, S., O’Neill, B. P., Marks, R. S., O’Fallon, J. R., & Kimmel, D. W. (2004). Immunomodulatory treatment trial for paraneoplastic neurological disorders. Neuro-Oncol., 6(1), 55–62. https://doi.org/10.1215/S1152851703000395.

  10. 10.

    Keime-Guibert, F., Graus, F., Fleury, A., et al. (2000). Treatment of paraneoplastic neurological syndromes with antineuronal antibodies (anti-Hu, anti-Yo) with a combination of immunoglobulins, cyclophosphamide, and methylprednisolone. Journal of Neurology, Neurosurgery, and Psychiatry, 68(4), 479–482.

  11. 11.

    Widdess-Walsh, P., Tavee, J. O., Schuele, S., & Stevens, G. H. (2003). Response to intravenous immunoglobulin in anti-Yo associated paraneoplastic cerebellar degeneration: Case report and review of the literature. Journal of Neuro-Oncology, 63(2), 187–190.

  12. 12.

    Keime-Guibert, F., Graus, F., Broët, P., et al. (1999). Clinical outcome of patients with anti-Hu-associated encephalomyelitis after treatment of the tumor. Neurology., 53(8), 1719–1723.

  13. 13.

    Titulaer, M. J., Soffietti, R., Dalmau, J., et al. (2011). Screening for tumours in paraneoplastic syndromes: Report of an EFNS task force. Eur J Neurol Off J Eur Fed Neurol Soc., 18(1), 19–e3. https://doi.org/10.1111/j.1468-1331.2010.03220.x.

  14. 14.

    Darnell, R. B., & Posner, J. B. (2006). Paraneoplastic syndromes affecting the nervous system. Seminars in Oncology, 33(3), 270–298. https://doi.org/10.1053/j.seminoncol.2006.03.008.

  15. 15.

    Pittock, S. J., Kryzer, T. J., & Lennon, V. A. (2004). Paraneoplastic antibodies coexist and predict cancer, not neurological syndrome. Annals of Neurology, 56(5), 715–719. https://doi.org/10.1002/ana.20269.

  16. 16.

    Horta, E. S., Lennon, V. A., Lachance, D. H., et al. (2014). Neural autoantibody clusters aid diagnosis of cancer. Clin Cancer Res Off J Am Assoc Cancer Res., 20(14), 3862–3869. https://doi.org/10.1158/1078-0432.CCR-14-0652.

  17. 17.

    Gorman, M. P. (2010). Update on diagnosis, treatment, and prognosis in opsoclonus-myoclonus-ataxia syndrome. Current Opinion in Pediatrics, 22(6), 745–750. https://doi.org/10.1097/MOP.0b013e32833fde3f.

  18. 18.

    Rosenfeld, M. R., Eichen, J. G., Wade, D. F., Posner, J. B., & Dalmau, J. (2001). Molecular and clinical diversity in paraneoplastic immunity to ma proteins. Annals of Neurology, 50(3), 339–348.

  19. 19.

    Hadjivassiliou, M., Alder, S. J., Van Beek, E. J. R., et al. (2009). PET scan in clinically suspected paraneoplastic neurological syndromes: A 6-year prospective study in a regional neuroscience unit. Acta Neurologica Scandinavica, 119(3), 186–193. https://doi.org/10.1111/j.1600-0404.2008.01089.x.

  20. 20.

    Irani, S. R., Michell, A. W., Lang, B., et al. (2011). Faciobrachial dystonic seizures precede Lgi1 antibody limbic encephalitis. Annals of Neurology, 69(5), 892–900. https://doi.org/10.1002/ana.22307.

  21. 21.

    Kalachikov, S., Evgrafov, O., Ross, B., et al. (2002). Mutations in LGI1 cause autosomal-dominant partial epilepsy with auditory features. Nature Genetics, 30(3), 335–341. https://doi.org/10.1038/ng832.

  22. 22.

    Pittock, S. J., & Vincent, A. (2016). Introduction to autoimmune neurology. Handbook of Clinical Neurology, 133, 3–14. https://doi.org/10.1016/B978-0-444-63432-0.00001-3.

  23. 23.

    Aalberse, R. C., Stapel, S. O., Schuurman, J., & Rispens, T. (2009). Immunoglobulin G4: an odd antibody. Clin Exp Allergy J Br Soc Allergy Clin Immunol., 39(4), 469–477. https://doi.org/10.1111/j.1365-2222.2009.03207.x.

  24. 24.

    Huijbers, M. G., Querol, L. A., Niks, E. H., et al. (2015). The expanding field of IgG4-mediated neurological autoimmune disorders. European Journal of Neurology, 22(8), 1151–1161. https://doi.org/10.1111/ene.12758.

  25. 25.

    Gastaldi, M., Thouin, A., & Vincent, A. (2016). Antibody-mediated autoimmune encephalopathies and immunotherapies. Neurother J Am Soc Exp Neurother., 13(1), 147–162. https://doi.org/10.1007/s13311-015-0410-6.

  26. 26.

    Irani, S. R., Bera, K., Waters, P., et al. (2010). N-methyl-D-aspartate antibody encephalitis: Temporal progression of clinical and paraclinical observations in a predominantly non-paraneoplastic disorder of both sexes. Brain: A Journal of Neurology, 133(Pt 6), 1655–1667. https://doi.org/10.1093/brain/awq113.

  27. 27.

    Graus, F., Vega, F., Delattre, J. Y., et al. (1992). Plasmapheresis and antineoplastic treatment in CNS paraneoplastic syndromes with antineuronal autoantibodies. Neurology., 42(3 Pt 1), 536–540.

  28. 28.

    Uchuya, M., Graus, F., Vega, F., Reñé, R., & Delattre, J. Y. (1996). Intravenous immunoglobulin treatment in paraneoplastic neurological syndromes with antineuronal autoantibodies. Journal of Neurology, Neurosurgery, and Psychiatry, 60(4), 388–392.

  29. 29.

    Leypoldt, F., & Wandinger, K.-P. (2014). Paraneoplastic neurological syndromes. Clinical and Experimental Immunology, 175(3), 336–348. https://doi.org/10.1111/cei.12185.

  30. 30.

    Stark, E., Wurster, U., Patzold, U., Sailer, M., & Haas, J. (1995). Immunological and clinical response to immunosuppressive treatment in paraneoplastic cerebellar degeneration. Archives of Neurology, 52(8), 814–818.

  31. 31.

    Shams’ili, S., de Beukelaar, J., Gratama, J. W., et al. (2006). An uncontrolled trial of rituximab for antibody associated paraneoplastic neurological syndromes. Journal of Neurology, 253(1), 16–20. https://doi.org/10.1007/s00415-005-0882-0.

  32. 32.

    Dalmau, J., Graus, F., Villarejo, A., et al. (2004). Clinical analysis of anti-Ma2-associated encephalitis. Brain: A Journal of Neurology, 127(Pt 8), 1831–1844. https://doi.org/10.1093/brain/awh203.

  33. 33.

    Höftberger, R., Titulaer, M. J., Sabater, L., et al. (2013). Encephalitis and GABAB receptor antibodies: Novel findings in a new case series of 20 patients. Neurology., 81(17), 1500–1506. https://doi.org/10.1212/WNL.0b013e3182a9585f.

  34. 34.

    Höftberger, R., van Sonderen, A., Leypoldt, F., et al. (2015). Encephalitis and AMPA receptor antibodies: Novel findings in a case series of 22 patients. Neurology., 84(24), 2403–2412. https://doi.org/10.1212/WNL.0000000000001682.

  35. 35.

    Hughes, E. G., Peng, X., Gleichman, A. J., et al. (2010). Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis. Journal of Neuroscience: The Official Journal of the Society for Neuroscience, 30(17), 5866–5875. https://doi.org/10.1523/JNEUROSCI.0167-10.2010.

  36. 36.

    Moscato, E. H., Peng, X., Jain, A., Parsons, T. D., Dalmau, J., & Balice-Gordon, R. J. (2014). Acute mechanisms underlying antibody effects in anti-N-methyl-D-aspartate receptor encephalitis. Annals of Neurology, 76(1), 108–119. https://doi.org/10.1002/ana.24195.

  37. 37.

    Dalmau, J., Lancaster, E., Martinez-Hernandez, E., Rosenfeld, M. R., & Balice-Gordon, R. (2011). Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurology, 10(1), 63–74. https://doi.org/10.1016/S1474-4422(10)70253-2.

  38. 38.

    Titulaer, M. J., McCracken, L., Gabilondo, I., et al. (2013). Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: An observational cohort study. Lancet Neurology, 12(2), 157–165. https://doi.org/10.1016/S1474-4422(12)70310-1.

  39. 39.

    Lee, W.-J., Lee, S.-T., Moon, J., et al. (2016). Tocilizumab in autoimmune encephalitis refractory to rituximab: An institutional cohort study. Neurotherapeutics., 13(4), 824–832. https://doi.org/10.1007/s13311-016-0442-6.

  40. 40.

    Kang, S., Tanaka, T., & Kishimoto, T. (2015). Therapeutic uses of anti-interleukin-6 receptor antibody. International Immunology, 27(1), 21–29. https://doi.org/10.1093/intimm/dxu081.

  41. 41.

    Heink, S., Yogev, N., Garbers, C., et al. (2017). Trans-presentation of IL-6 by dendritic cells is required for the priming of pathogenic TH17 cells. Nature Immunology, 18(1), 74–85. https://doi.org/10.1038/ni.3632.

  42. 42.

    Chihara, N., Aranami, T., Sato, W., et al. (2011). Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica. Proceedings of the National Academy of Sciences of the United States of America, 108(9), 3701–3706. https://doi.org/10.1073/pnas.1017385108.

  43. 43.

    Ayzenberg, I., Kleiter, I., Schröder, A., et al. (2013). Interleukin 6 receptor blockade in patients with neuromyelitis optica nonresponsive to anti-CD20 therapy. JAMA Neurology, 70(3), 394–397. https://doi.org/10.1001/jamaneurol.2013.1246.

  44. 44.

    Krogias, C., Hoepner, R., Müller, A., Schneider-Gold, C., Schröder, A., & Gold, R. (2013). Successful treatment of anti-Caspr2 syndrome by interleukin 6 receptor blockade through tocilizumab. JAMA Neurology, 70(8), 1056–1059. https://doi.org/10.1001/jamaneurol.2013.143.

  45. 45.

    Ringelstein, M., Ayzenberg, I., Harmel, J., et al. (May 2015). Long-term therapy with interleukin 6 receptor blockade in highly active Neuromyelitis Optica Spectrum disorder. JAMA Neurology. https://doi.org/10.1001/jamaneurol.2015.0533.

  46. 46.

    Ogata, A., Kato, Y., Higa, S., & Yoshizaki, K. (2019). IL-6 inhibitor for the treatment of rheumatoid arthritis: A comprehensive review. Modern Rheumatology, 29(2), 258–267. https://doi.org/10.1080/14397595.2018.1546357.

  47. 47.

    Richardson, P. G., Schlossman, R., Hideshima, T., & Anderson, K. C. (2005). New treatments for multiple myeloma. Oncol Williston Park N, 19(14), 1781–1792 discussion 1792, 1795-1797.

  48. 48.

    Meister, S., Schubert, U., Neubert, K., et al. (2007). Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition. Cancer Research, 67(4), 1783–1792. https://doi.org/10.1158/0008-5472.CAN-06-2258.

  49. 49.

    Berges, C., Haberstock, H., Fuchs, D., et al. (2008). Proteasome inhibition suppresses essential immune functions of human CD4+ T cells. Immunology., 124(2), 234–246. https://doi.org/10.1111/j.1365-2567.2007.02761.x.

  50. 50.

    Verbrugge, S. E., Scheper, R. J., Lems, W. F., de Gruijl, T. D., & Jansen, G. (2015). Proteasome inhibitors as experimental therapeutics of autoimmune diseases. Arthritis Research & Therapy, 17, 17. https://doi.org/10.1186/s13075-015-0529-1.

  51. 51.

    Zinser, E., Rössner, S., Littmann, L., Lüftenegger, D., Schubert, U., & Steinkasserer, A. (2009). Inhibition of the proteasome influences murine and human dendritic cell development in vitro and in vivo. Immunobiology., 214(9–10), 843–851. https://doi.org/10.1016/j.imbio.2009.06.018.

  52. 52.

    Blanco, B., Sánchez-Abarca, L. I., Caballero-Velázquez, T., Santamaría, C., Inogés, S., & Pérez-Simón, J. A. (2011). Depletion of alloreactive T-cells in vitro using the proteasome inhibitor bortezomib preserves the immune response against pathogens. Leukemia Research, 35(10), 1412–1415. https://doi.org/10.1016/j.leukres.2011.05.018.

  53. 53.

    Alexander, T., Sarfert, R., Klotsche, J., et al. (2015). The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus. Annals of the Rheumatic Diseases, 74(7), 1474–1478. https://doi.org/10.1136/annrheumdis-2014-206016.

  54. 54.

    Lassoued, S., Moyano, C., Beldjerd, M., Pauly, P., Lassoued, D., & Billey, T. (February 2019). Bortezomib improved the joint manifestations of rheumatoid arthritis in three patients. Jt Bone Spine Rev Rhum. https://doi.org/10.1016/j.jbspin.2019.01.019.

  55. 55.

    Alexander, T., Cheng, Q., Klotsche, J., et al. (2018). Proteasome inhibition with bortezomib induces a therapeutically relevant depletion of plasma cells in SLE but does not target their precursors. European Journal of Immunology, 48(9), 1573–1579. https://doi.org/10.1002/eji.201847492.

  56. 56.

    Verbrugge, S. E., Al, M., Assaraf, Y. G., et al. (2013). Overcoming bortezomib resistance in human B cells by anti-CD20/rituximab-mediated complement-dependent cytotoxicity and epoxyketone-based irreversible proteasome inhibitors. Experimental Hematology & Oncology, 2(1), 2. https://doi.org/10.1186/2162-3619-2-2.

  57. 57.

    Behrendt, V., Krogias, C., Reinacher-Schick, A., Gold, R., & Kleiter, I. (2016). Bortezomib treatment for patients with anti-N-methyl-d-aspartate receptor encephalitis. JAMA Neurology, 73(10), 1251–1253. https://doi.org/10.1001/jamaneurol.2016.2588.

  58. 58.

    Scheibe, F., Prüss, H., Mengel, A. M., et al. (2017). Bortezomib for treatment of therapy-refractory anti-NMDA receptor encephalitis. Neurology., 88(4), 366–370. https://doi.org/10.1212/WNL.0000000000003536.

  59. 59.

    Sveinsson, O., Granqvist, M., Forslin, Y., Blennow, K., Zetterberg, H., & Piehl, F. (2017). Successful combined targeting of B- and plasma cells in treatment refractory anti-NMDAR encephalitis. Journal of Neuroimmunology, 312, 15–18. https://doi.org/10.1016/j.jneuroim.2017.08.011.

  60. 60.

    Schroeder, C., Back, C., Koc, Ü., et al. (2018). Breakthrough treatment with bortezomib for a patient with anti-NMDAR encephalitis. Clinical Neurology and Neurosurgery, 172, 24–26. https://doi.org/10.1016/j.clineuro.2018.06.005.

  61. 61.

    Schneider-Gold, C., Reinacher-Schick, A., Ellrichmann, G., & Gold, R. (2017). Bortezomib in severe MuSK-antibody positive myasthenia gravis: First clinical experience. Therapeutic Advances in Neurological Disorders, 10(10), 339–341. https://doi.org/10.1177/1756285617721093.

  62. 62.

    Kohler, S., Märschenz, S., Grittner, U., Alexander, T., Hiepe, F., & Meisel, A. (2019). Bortezomib in antibody-mediated autoimmune diseases (TAVAB): Study protocol for a unicentric, non-randomised, non-placebo controlled trial. BMJ Open, 9(1), e024523. https://doi.org/10.1136/bmjopen-2018-024523.

  63. 63.

    Jarius, S., & Wildemann, B. (2015). ‘Medusa-head ataxia’: The expanding spectrum of Purkinje cell antibodies in autoimmune cerebellar ataxia. Part 1: Anti-mGluR1, anti-Homer-3, anti-Sj/ITPR1 and anti-CARP VIII. Journal of Neuroinflammation, 12. https://doi.org/10.1186/s12974-015-0356-y.

  64. 64.

    de Graaff, E., Maat, P., Hulsenboom, E., et al. (2012). Identification of delta/notch-like epidermal growth factor-related receptor as the Tr antigen in paraneoplastic cerebellar degeneration. Annals of Neurology, 71(6), 815–824. https://doi.org/10.1002/ana.23550.

  65. 65.

    Miske, R., Gross, C. C., Scharf, M., et al. (2017). Neurochondrin is a neuronal target antigen in autoimmune cerebellar degeneration. Neurol Neuroimmunol Neuroinflammation., 4(1), e307. https://doi.org/10.1212/NXI.0000000000000307.

  66. 66.

    Pitarokoili, K., Yoon, M.-S., Kröger, I., Reinacher-Schick, A., Gold, R., & Schneider-Gold, C. (2017). Severe refractory CIDP: A case series of 10 patients treated with bortezomib. Journal of Neurology, 264(9), 2010–2020. https://doi.org/10.1007/s00415-017-8599-4.

  67. 67.

    Palumbo, A., Chanan-Khan, A., Weisel, K., et al. (2016). Daratumumab, Bortezomib, and dexamethasone for multiple myeloma. The New England Journal of Medicine, 375(8), 754–766. https://doi.org/10.1056/NEJMoa1606038.

  68. 68.

    Minarik, J., Pavlicek, P., Pour, L., et al. (2015). Subcutaneous bortezomib in multiple myeloma patients induces similar therapeutic response rates as intravenous application but it does not reduce the incidence of peripheral neuropathy. PLoS One, 10(4), e0123866. https://doi.org/10.1371/journal.pone.0123866.

  69. 69.

    Moreau, P., Hulin, C., Marit, G., et al. (2010). Stem cell collection in patients with de novo multiple myeloma treated with the combination of bortezomib and dexamethasone before autologous stem cell transplantation according to IFM 2005-01 trial. Leukemia., 24(6), 1233–1235. https://doi.org/10.1038/leu.2010.82.

  70. 70.

    Sicre de Fontbrune, F., & Peffault de Latour, R. (2018). Ten years of clinical experience with Eculizumab in patients with paroxysmal nocturnal hemoglobinuria. Seminars in Hematology, 55(3), 124–129. https://doi.org/10.1053/j.seminhematol.2018.04.001.

  71. 71.

    Dalakas, M. C. (2019). Immunotherapy in myasthenia gravis in the era of biologics. Nature Reviews. Neurology, 15(2), 113–124. https://doi.org/10.1038/s41582-018-0110-z.

  72. 72.

    Alexion Announces Successful Phase 3 PREVENT Study of Soliris® (Eculizumab) in Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD) | Alexion Pharmaceuticals, Inc. https://news.alexionpharma.com/press-release/product-news/alexion-announces-successful-phase-3-prevent-study-soliris-eculizumab-pat. Accessed April 24, 2019.

  73. 73.

    Pittock, S. J., Lennon, V. A., McKeon, A., et al. (2013). Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: An open-label pilot study. Lancet Neurology, 12(6), 554–562. https://doi.org/10.1016/S1474-4422(13)70076-0.

  74. 74.

    McNamara LA, Topaz N, Wang X, Hariri S, Fox L, MacNeil JR. High Risk for Invasive Meningococcal Disease Among Patients Receiving Eculizumab (Soliris) Despite Receipt of Meningococcal Vaccine. MMWR Morb Mortal Wkly Rep. 2017;66(27):734–737. doi:https://doi.org/10.15585/mmwr.mm6627e1

  75. 75.

    Forsthuber, T. G., Cimbora, D. M., Ratchford, J. N., Katz, E., & Stüve, O. (2018). B cell-based therapies in CNS autoimmunity: Differentiating CD19 and CD20 as therapeutic targets. Therapeutic Advances in Neurological Disorders, 11, 1756286418761697. https://doi.org/10.1177/1756286418761697.

  76. 76.

    Inebilizumab, a B Cell-Depleting Anti-CD19 Antibody for the Treatment of Autoimmune Neurological Diseases: Insights from Preclinical Studies. - PubMed - NCBI. https://www.ncbi.nlm.nih.gov/pubmed/?term=inebilizumab+chen. Accessed April 24, 2019.

  77. 77.

    Schiopu, E., Chatterjee, S., Hsu, V., et al. (2016). Safety and tolerability of an anti-CD19 monoclonal antibody, MEDI-551, in subjects with systemic sclerosis: A phase I, randomized, placebo-controlled, escalating single-dose study. Arthritis Research & Therapy, 18. https://doi.org/10.1186/s13075-016-1021-2.

  78. 78.

    Agius, M. A., Klodowska-Duda, G., Maciejowski, M., et al. (2019). Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: Results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose study. Mult Scler Houndmills Basingstoke Engl., 25(2), 235–245. https://doi.org/10.1177/1352458517740641.

Download references

Acknowledgements

Not applicable.

Funding

None.

Author information

IA, SF, DR and LT prepared the manuscript. DR, LT and VB prepared description of reported cases. RG and SF critically revised the manuscript for intellectual content. All authors read and approved the final manuscript.

Correspondence to Ilya Ayzenberg.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Both patients described in the manuscript gave their informed consent.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Ayzenberg, I., Faissner, S., Tomaske, L. et al. General principles and escalation options of immunotherapy in autoantibody-associated disorders of the CNS. Neurol. Res. Pract. 1, 32 (2019) doi:10.1186/s42466-019-0037-x

Download citation